Page 6 - Astrazeneca

AstraZeneca's nasal Covid vaccine not as effective as expected: Study

AstraZeneca's intranasally-administered vaccine against COVID-19 did not perform as expected in a small study published on Tuesday, suggesting there are likely to be challenges in making nasal sprays a reliable option. The findings from a Phase 1 clinical trial, published in the journal eBioMedicine, show mucosal antibody responses were generated in a minority of participants. Systemic immune responses, which involves many other immune cells, to intranasal vaccination were also weaker compared with intramuscular vaccination, the researchers said. The study was performed in collaboration with the University of Oxford and used the same vaccine based on the ChAdOx1 adenovirus vector, as is already licensed for use by injection. The ChAdOx1 vector used in the vaccine is a weakened version of a common cold virus (adenovirus) that has been genetically modified so it is impossible for it to replicate in humans. The latest study is thought to be the first to have published data from ...

Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

AstraZeneca India gets DCGI approval to market drug treating breast cancer

Drug firm AstraZeneca India on Friday said it has received an approval from the Drugs Controller General of India to market its drug for the treatment of breast cancer. The Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early breast cancer, who have previously been treated with neoadjuvant or adjuvant chemotherapy. The approval was based on results from the OlympiA Phase III trial, which suggested that Olaparib demonstrated a statistically significant and clinically meaningful improvement, with an overall survival benefit, AstraZeneca India said in a statement. With the DCGI's nod, Lynparza is now approved in the US, EU, Japan, India and several other countries for the treatment of early-stage breast cancer, it added. Currently, Lynparza is the first and only approved medicine targeting BRCA (Breast Cancer gene) mutations in early-stage breast cancer. "The regulatory approval of Lynparza...reinfor

Canada to throw out 13.6 million doses of AstraZeneca Covid vaccine

Canada is going to throw out about 13.6 million doses of the Oxford-AstraZeneca COVID-19 vaccine because it couldn't find any takers for it either at home or abroad

Covid vaccines prevented 20 million deaths in first year of rollout: Study

While more than 7 million deaths were likely averted in countries covered by Covax, the WHO-backed distribution program, the research nonetheless highlights the devastation caused by uneven access

AstraZeneca Covid booster shot effective against severe disease: UK study

The third dose of AstraZeneca COVID vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer, according to a study in the UK

AstraZeneca says its Covid shot still has role despite global glut

AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said

EU regulator advises AstraZeneca's Covid drug be cleared

The drug was previously cleared by the US Food and Drug Administration in December for people with serious health problems or allergies who can't get adequate protection from vaccination

AstraZeneca Covid drug neutralises Omicron sub-variants in lab study

Evusheld was tested against the BA.1, BA.1.1, and BA.2 sub-variants of Omicron and it was also shown in the study to limit inflammation in the lungs - a critical symptom in severe Covid-19 infections

Short AstraZeneca shelf life complicates vaccine rollout to world's poorest

Many more vaccines are expected to be rejected as African nations and Covax said that from January they would not accept vaccines with less than two-and-a-half months' shelf life

Israel okays AstraZeneca Covid drug for people with weakened immunity

The drug has been shown to reduce severe morbidity and mortality from Covid by 83 per cent

AstraZeneca sees $4 bn in Covid vaccine sales in Q4 as revenue soars

The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates

AstraZeneca booster generates higher antibodies against Omicron: Data

The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said

UK marks Oxford/AstraZeneca Covid-19 vaccine's one-year anniversary

Our fight against COVID in the UK and around the world would not have been possible without the Oxford/AstraZeneca vaccine, said PM Boris Johnson

Oxford-AstraZeneca vaccine behind lower Covid deaths in UK, says expert

'If you look across Europe, with the rise in cases, there's also a corresponding lagged rise in deaths, but not in the UK,' says Dr Clive Dix, former chairman of the UK's Vaccine Task Force

AstraZeneca says its antibody drug Evusheld can fight Omicron variant

Evusheld is one of only two antibody therapies authorised for use that showed neutralising activity against Omicron and against all other variants of concern in these two studies.

Serum Institute on the up as Oxford study backs AstraZ booster for Omicron

Vaxzevria significantly boosts antibodies against the rapidly spreading variant of the coronavirus, shows study

AstraZeneca booster shot effective against Omicron: Oxford lab study

After a three-dose course of the vaccine, neutralising levels against Omicron were similar to those against the virus's Delta variant after two doses

'USFDA study shows Evusheld retains neutralising activity against Omicron'

The study was done independently by investigators at the US Food and Drug Administration (USFDA), Center for Biologics Evaluation and Research.

Billionaire Poonawalla family pledges $66 mn to Oxford for research campus

The pledge builds on the collaboration between Oxford University, AstraZeneca and SII, the world's largest maker of vaccines